Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Traws Pharma, Inc. - Common Stock (NQ:TRAW)

0.5452 +0.0052 (+0.96%)
Streaming Delayed Price Updated: 10:30 AM EDT, Aug 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 16,673
Open 0.5400
Bid (Size) 0.5401 (100)
Ask (Size) 0.5502 (400)
Prev. Close 0.5400
Today's Range 0.5400 - 0.5502
52wk Range 0.4301 - 3.265
Shares Outstanding 5,564,315
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program
Resubmission of updated data package to MHRA, expected in 3Q 2026, to enable Phase 2a human influenza Challenge study to proceed 
From Traws Pharma, Inc.
Via GlobeNewswire

Performance

YTD
-59.0%
-59.0%
1 Month
-10.7%
-10.7%
3 Month
-69.0%
-69.0%
6 Month
-72.2%
-72.2%
1 Year
-61.6%
-61.6%

More News

Read More
Monday's session: top gainers and losers ↗
Via Chartmill
Gapping stocks in Monday's session ↗
Via Chartmill
TRAW Stock Slides In Volatile Session –  What’s The Latest On Its Phase 2 Trial For COVID-19 Treatment? ↗
Via Stocktwits
Monday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
Traws Pharma Provides Regulatory Update on Influenza Program
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results
From Traws Pharma, Inc.
Via GlobeNewswire
Unusual volume stocks are being observed in Monday's session. ↗
Via Chartmill
Friday's session: top gainers and losers ↗
Via Chartmill
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
Gapping stocks in Friday's session ↗
Via Chartmill
Which stocks are moving before the opening bell on Friday? ↗
Via Chartmill
News headline image
Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
TRAWS PHARMA INC (NASDAQ:TRAW) Reports 2025 Earnings Beat Amid Dilutive $60M PIPE Financing and FDA Hold ↗
Via Chartmill
Topics Earnings
News headline image
Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Traws Pharma Announces Up to $60 Million Private Placement Financing
From Traws Pharma, Inc.
Via GlobeNewswire
Top stock movements in today's session. ↗
Via Chartmill
Gapping stocks in Thursday's session ↗
Via Chartmill
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
From Traws Pharma, Inc.
Via GlobeNewswire
Top movers analysis in the middle of the day on 2026-01-28: top gainers and losers in today's session. ↗
Via Chartmill
News headline image
Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients
From Traws Pharma, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Traws Pharma, Inc. - Common Stock publicly traded?
Yes, Traws Pharma, Inc. - Common Stock is publicly traded.
What exchange does Traws Pharma, Inc. - Common Stock trade on?
Traws Pharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Traws Pharma, Inc. - Common Stock?
The ticker symbol for Traws Pharma, Inc. - Common Stock is TRAW on the Nasdaq Stock Market
What is the current price of Traws Pharma, Inc. - Common Stock?
The current price of Traws Pharma, Inc. - Common Stock is 0.5452
When was Traws Pharma, Inc. - Common Stock last traded?
The last trade of Traws Pharma, Inc. - Common Stock was at 08/18/26 10:30 AM ET
What is the market capitalization of Traws Pharma, Inc. - Common Stock?
The market capitalization of Traws Pharma, Inc. - Common Stock is 3.03M
How many shares of Traws Pharma, Inc. - Common Stock are outstanding?
Traws Pharma, Inc. - Common Stock has 3M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS